167758-88-5

Basic information

• Product Name: ethyl 4-fluoro-2-methylbenzoate
• Synonyms: ethyl 4-fluoro-2-methylbenzoate;4-Fluoro-2-methylbenzoic acid ethyl ester
• CAS NO: 167758-88-5
• Molecular Formula: C₁₀H₁₁FO₂
• Molecular Weight: 182.1915432
• Mol File: 167758-88-5.mol

Chemical Properties

• Boiling Point: 226.2°C at 760 mmHg
• Flash Point: 88.2°C
• Appearance: /
• Density: 1.108g/cm³
• Vapor Pressure: 0.0828mmHg at 25°C
• Refractive Index: 1.489
• CAS DataBase Reference: ethyl 4-fluoro-2-methylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-fluoro-2-methylbenzoate(167758-88-5)
• EPA Substance Registry System: ethyl 4-fluoro-2-methylbenzoate(167758-88-5)

Safety Data

• Hazardous Substances Data: 167758-88-5(Hazardous Substances Data)

Usage

Uses

Used in Flavor and Fragrance Industry:
Ethyl 4-fluoro-2-methylbenzoate is utilized as a flavoring agent and fragrance ingredient, particularly in food and cosmetic products, due to its fruity scent and ability to enhance the sensory experience of these products.
Used in Pharmaceutical Synthesis:
In the pharmaceutical industry, ethyl 4-fluoro-2-methylbenzoate serves as a key intermediate in the synthesis of various medicinal compounds, leveraging its unique aromatic structure to contribute to the development of new drugs.
Used in Agrochemical Synthesis:
Similarly, in agrochemical production, ethyl 4-fluoro-2-methylbenzoate is employed as a building block in the creation of different agrochemicals, where its aromatic properties are harnessed to improve the effectiveness of these products.
Safety Considerations:
Given its classification as a potentially hazardous chemical, ethyl 4-fluoro-2-methylbenzoate requires careful handling and adherence to proper safety precautions to mitigate risks associated with its use.

InChI:InChI=1/C10H11FO2/c1-3-13-10(12)9-5-4-8(11)6-7(9)2/h4-6H,3H2,1-2H3

Upstream product

• 452-63-1 2-Bromo-5-fluorotoluene 
• 541-41-3 chloroformic acid ethyl ester 
• 321-21-1 4-fluoro-2-methylbenzoic acid 
• 75-03-6 ethyl iodide 
• 64-17-5 ethanol 

Downstream Products

• 1358575-02-6 4-(3-(3-fluoro-5-(trifluoromethyl)benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide 

Relevant articles and documents

Pyridazone derivative and its uses

The present invention belongs to the pharmaceutical field, specifically relates to a pyridazone derivative and its uses, compounds thereof and pharmaceutically acceptable salts, solvates including hydrates, polycrystallines, prodrugs, co-crystallines, tau

Influenza virus replication inhibitor and uses thereof

The invention belongs to the field of medicines, and particularly relates to a new compound serving as an influenza virus replication inhibitor, a preparation method thereof, a pharmaceutical composition containing the compound, and application of the compound and the pharmaceutical composition in the treatment of influenza. The compound is a compound shown in a formula (I) or a stereoisomer, a tautomer, oxynitride, a solvate, a metabolite, a pharmaceutically acceptable salt or prodrugs of the compound shown in the formula (I). The compound can well inhibit influenza viruses, and/or has lowercytotoxicity, more excellent in-vivo metabolic dynamics properties and in-vivo pharmacodynamic properties.

INFLUENZA VIRUS REPLICATION INHIBITOR AND USES THEREOF

The invention belongs to the field of medicine, and particularly relates to a novel compound as a replication inhibitor of influenza virus and a preparation method thereof, a pharmaceutical composition comprising the compound and use of the compound and pharmaceutical composition thereof in treating influenza. The present invention provides a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, The compound of the present invention can inhibit influenza virus well, and/or has lower cytotoxicity, better in vivo pharmacokinetic properties and in vivo pharmacodynamic properties.

Design, synthesis, and pharmacological evaluation of 4-azolyl-benzamide derivatives as novel GPR52 agonists

G protein-coupled receptor 52 (GPR52) agonists are expected to improve the symptoms of psychiatric disorders. During exploration for a novel class of GPR52 agonists with good pharmacokinetic profiles, we synthesized 4-(3-(3-fluoro-5-(trifluoromethyl)benzyl)-5-methyl-1H-1,2,4-triazol-1-yl)-2-methylbenzamide (4u; half maximal effective concentration (EC50)?=?75?nM, maximal response (Emax)?=?122%) starting from a high-throughput screening hit 3 (EC50?=?470?nM, Emax?=?56%). The structural features of a reported GPR52 agonist were applied to 3, led to design 4-azolylbenzamides as novel GPR52 agonists. A structure–activity relationship study of 4-azolylbenzamide resulted in the design of the 1,2,4-triazole derivative 4u, which demonstrated excellent bioavailability in rats (F?=?53.8%). Oral administration of 4u (10?mg/kg) significantly suppressed methamphetamine-induced hyperlocomotion in mice. Thus, 4u is a promising lead compound for drug discovery research of GPR52 agonists.

Novel cyclic amide derivatives

Novel compounds represented by the following formula (I) that act as a ligand to sigma receptor/binding cite and a medicament comprising the same as an active ingredient: wherein X represents an alkyl group, an aryl group, a heterocyclic group or the like; Q represents a group represented by —CH2—, —CO—, —O—, —CH(OR7)— or the like wherein R7 represents a hydrogen atom, an alkyl group or the like; n represents an integer of from 0 to 5; R1 and R2 each represent a hydrogen atom, an alkyl group or the like; B represents either of the following groups: wherein R3, R4, R5, and R6 each represent a hydrogen atom, a halogen atom, an alkoxyl group or the like; m represents 1 or 2; and the ring of: represents an aromatic heterocyclic ring.